Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $732 billion, has been ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December scripts boost. The stock is attractively valued at current levels. Eli Lilly ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

Aims to revolutionize pharmaceutical manufacturing with focus on advanced aseptic processing technology.

Danish drugmaker Novo Nordisk reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...

Eli Lilly’s (LLY ... causing persistent shortages. Key Points: Manufacturing constraints hamper Lilly and Novo Nordisk’s ability to meet drug demand. 2025 revenue guidance of $58–$61 ...

Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing Consortium aimed at pioneering new advances in how medicines are produced.

Eli Lilly (LLY) revised its revenue outlook ... expects to see continued demand for weight-loss drugs in 2025. As a result, he said manufacturing capacity will be about 60% higher in the first ...